2 registrations that name brown Rice Protein as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
2US sites across 2 states
1
2 to 4
5 to 19
20 or more
All 2 registrations
RecruitingNCT03990909
Pilot Study of BCAA on Sleep
No phase
Portland VA Medical Center
About 300 people
Started Mar 1, 2019
In plain words A study of brown Rice Protein in people 18 to 89, run by Portland VA Medical Center. It plans to enroll about 300 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 89. Conditions: Sleep Disorder; Traumatic Brain Injury.
Individuals will be recruited from the VA Portland Health Care System and the community affiliated with Oregon Health \& Science University. Traumatic brain injury status will be assessed as a contributing factor. Subjects will be randomized to one of 3 groups (BCAA or one of 2 placebo conditions) and instructed to consume study product twice daily for 21 days. Self-report questionnaires, wrist actigraphy, pressure pain testing, and cognitive function will be assessed pre and post the experimental period.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT06967428
Effect of Metabolic Modulation on a Post-acute COVID-19 Vaccination Syndrome (PACVS) Cohort
Phase 2
Independent Medical Alliance
About 100 people
Starts Sep 1, 2025 (estimated)
In plain words A Phase 2 study of brown Rice Protein in people 16 and older, run by Independent Medical Alliance. It plans to enroll about 100 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 16 and older. Conditions: Vaccine Adverse Reaction; Post Acute Covid-19 Vaccination Syndrome.
Persistent fatigue lasting more than 6 months
Received at least one dose of a Covid-19 vaccine, after which they experienced fatigue symptoms (symptom onset within two weeks of vaccination)
Laboratory result showing persistent spike protein in blood OR presence of spike protein antibodies with SARS-CoV-2 nucleocapsid antibodies negative.
The exclusion criteria are on the listing.
What it tests, as registered
Combined metabolic modulator; Rice Protein Powder with Vitamin C
Registered summary
The goal of this clinical trial is to evaluate whether metabolic modulation with a combined nutraceutical product can improve symptoms and metabolic health in adults diagnosed with post-acute Covid-19 vaccination syndrome (PACVS), a condition characterized by persistent fatigue and exercise intolerance attributed to Covid-19 vaccination and confirmed by laboratory testing. The full summary is on the listing.